IGFBP2 and lung carcinoma: As shown in recent studies, elevated IGFBP2 expression and activated FAK have been causally associated with dasatinib resistance in lung cancer cells, and administration of a combination of dasatinib with an FAK inhibitor can overcome this resistance [24].